Partnership Points to New Path Forward For Drug Approval and Clinical Research 2

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Registration Trial Design

Lung-MAP is designed to provide a fast, efficient path to full approval, said Roy Herbst, co-chair of the trial’s steering committee and co-chair of its executive operations group. The idea is to get drugs to patients throughout the community, going seamlessly from a phase II portion to phase III, with all patients counting toward registration.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login